[Evaluation of the therapeutic activity of and gastric lesions due to new NSAID versus placebo in patients with osteoarticular diseases]. / Valutazione dell'attività terapeutica e della gastrolesività di un nuovo FANS in confronto a placebo in pazienti con patologie osteoarticolari.

Oral amtolmetineguacyl 600 mg/day in a single blind comparative trial with placebo carried out in 24 patients suffering from rheumatic disorders of varying severity, reduced statistically all the symptomatology correlated to inflammation. Moreover our results indicate a lack of any gastric problem even in patient with a previous history of intolerance to other NSAIDs.

[Clinical trial comparing a new NSAID with 2 different dosages and diclofenac in patients with arthralgia in acute phase]. / Studio clinico comparato fra un nuovo FANS con due posologie diversifcate e diclofenac in pazienti con artralgie in fase acuta.

In this study 30 athletes suffering from acute post-traumatic arthralgia were divided into 3 groups: 10 were treated with Amtolmetineguacil at the following dosages, 600 mg by os twice daily the first two days followed by 600 mg once daily for 19 days (Group A1); 10 patients treated with Amtolmetineguacil 600 mg twice daily for 21 days (Group A2); 10 patients treated with diclofenac 50 mg twice daily by os for 21 days (Group V). The dosage used in Group A1 was as efficacious as that used in Group A2. Furthermore Amtolmetineguacil was better tolerated than diclofenac.

Physical exercise stimulates marked concomitant release of beta-endorphin and adrenocorticotropic hormone (ACTH) in peripheral blood in man.

ACTH and beta-endorphin have been evaluated by means of a specific and sensitive radioimmunoassay in athletes reaching a status of physical stress. A concomitant marked increase of these 2 peptides has been recorded. The implications of this finding lead to the conclusion that stress stimulates the synthesis of the common precursor (31 K) in the pituitary.

Effects of orally administered oestradiol decanoate on plasma oestradiol, oestrone and gonadotrophin levels, vaginal cytology, cervical mucus and endometrium in ovariectomized women.

Six ovariectomized women with the uterus left in situ were given a daily oral dose of 0.5 mg of oestradiol decaneoate in oil for 14 days. After a single dose of oestradiol decanoate mean plasma oestradiol rose from 26.8 pg/ml to 66.8 pg/ml within 30 min. There was a further rise to 100-110 pg/ml (P less than 0.001) remaining at the same level over a 24 h period. On repeated daily administration of oestradiol decanoate this rise continued reaching the mean value of 187.1 pg/ml (P less than 0.001) at 2 weeks, while plasma oestrone remained at the same level (147.1 pg/ml) as it was at 24 h. The ratio of plasma oestrone:oestradiol was less than 1 at 2 weeks. Plasma FSH and LH fell progressively during the medication. Changes of the Maturation Index, cervical mucus Ferning and Spinnbarkeit demonstrated the strong 'peripheral' activity of this dose of oestradiol decanoate. All endometrial specimens showed late proliferative changes at 2 weeks. It was concluded that the favourable properties of oestradiol decanoate offer new possibilities for a more physiological oestrogen supplementation therapy.